Cardiac Coherence and the Effectiveness of Cardiovascular Biofeedback in the Nursing Team: A Randomized Clinical Trial

This study investigated the effectiveness of **cardiovascular biofeedback** as an intervention. Cardiovascular biofeedback is a mind-body technique that uses real-time physiological data, in this case, heart rate variability, to help individuals learn to self-regulate their physiological responses. The core mechanism involves guided, conscious deep breathing exercises designed to synchronize heart rhythms with breathing patterns, thereby enhancing a state known as "cardiac coherence." This state is associated with increased activation of the parasympathetic nervous system, which is responsible for the body's "rest and digest" functions, promoting relaxation and recovery.

The intervention group received training and practice with this cardiovascular biofeedback technique. The specific tool used was the EmWave Pro Plus®, which provides visual and auditory feedback on heart rhythm patterns, guiding users to achieve higher levels of coherence.

The **comparator** was a **placebo group**. While the abstract doesn't detail the exact nature of the placebo, in biofeedback studies, a placebo often involves a similar device or procedure but without the active biofeedback component (e.g., a device that provides random feedback, or a sham intervention that looks similar but doesn't measure or respond to physiological data). The purpose of a placebo is to control for the psychological effects of receiving an intervention, such as expectation, attention from researchers, and the novelty of the experience.

The **outcome measures** were specific parameters related to **heart rate variability (HRV)**. HRV is the variation in the time interval between consecutive heartbeats. It's a non-invasive measure that reflects the balance between the sympathetic (fight-or-flight) and parasympathetic (rest-and-digest) branches of the autonomic nervous system. Higher HRV generally indicates better adaptability and health. The study focused on two key HRV parameters:

1. **Cardiac coherence:** This is a specific state of physiological function where the heart's rhythm becomes highly ordered and synchronized, often appearing as a smooth, sine-wave-like pattern in heart rate variability. It's considered a marker of optimal autonomic nervous system balance and emotional regulation. The EmWave Pro Plus® device specifically quantifies this state.

2. **rMSSD (root mean square of successive differences):** This is a widely recognized time-domain measure of HRV. It reflects the beat-to-beat variance in heart rate and is strongly correlated with parasympathetic nervous system activity. A higher rMSSD value generally indicates greater parasympathetic influence and better vagal tone, which is associated with relaxation, stress resilience, and overall cardiovascular health.

The objective was to determine if the cardiovascular biofeedback intervention could improve these HRV parameters in the target population.

The study included **115 nursing professionals**. This specific population was chosen because healthcare professionals, particularly nurses, are known to experience high levels of occupational stress, which can negatively impact their psycho-emotional health and physiological well-being. The researchers aimed to investigate if biofeedback could be a useful tool for this high-stress group.

The participants were working in **clinical and surgical inpatient units at a university hospital**. This setting is important because it implies a demanding work environment with significant stressors, such as long shifts, critical patient care, emotional burden, and high responsibility.

A crucial **inclusion criterion** for participation was that individuals presented an **overall stress level higher than 1, according to the Stress Symptom Scale**. This indicates that the study specifically targeted individuals who were already experiencing some degree of stress, making them a relevant population to test an intervention aimed at stress reduction and physiological recovery. The abstract does not specify the exact scale used (e.g., Perceived Stress Scale, Holmes-Rahe Stress Inventory), nor its scoring range, but the threshold of "higher than 1" suggests a quantitative measure of stress symptoms. This selection criterion ensures that the participants were indeed a group that could potentially benefit from a stress-reducing intervention.

The abstract does not provide details on age, gender distribution, or other demographic characteristics of the participants, nor does it mention any exclusion criteria beyond the stress level. However, the focus on "nursing professionals" suggests a predominantly female population, given the demographics of the nursing profession in many parts of the world.

The primary method for assessing the outcome measures was the use of the **EmWave Pro Plus® device**. This is a commercially available biofeedback system developed by HeartMath Institute.

Here's how it works and what it measures:

**Photoplethysmography (PPG):** The EmWave Pro Plus® uses a sensor (typically clipped to an earlobe or fingertip) that employs photoplethysmography. PPG is an optical technique that detects changes in blood volume in the microvascular bed of tissue. As the heart beats, blood flows through the capillaries, causing slight changes in tissue opacity. The sensor emits light (often infrared) and measures the amount of light reflected or transmitted, which varies with blood volume. These variations correspond to the pulsatile component of the cardiac cycle, allowing the device to accurately detect each heartbeat.

**Quantifying Physiological Data:** From the detected heartbeats, the EmWave Pro Plus® calculates the time intervals between successive heartbeats (RR intervals). These RR intervals are then used to derive heart rate variability (HRV) parameters.

**Cardiac Coherence:** The device's proprietary algorithms analyze the patterns of HRV to determine the degree of "cardiac coherence." It typically presents this as a score or visual representation (e.g., a graph showing a smooth, sine-wave-like pattern of heart rhythm, or a color-coded indicator). Higher scores or more stable, coherent patterns indicate greater synchronization between heart rhythm and breathing, reflecting a more balanced and efficient autonomic nervous system state.

**rMSSD:** While the EmWave Pro Plus® is primarily known for its coherence feedback, it can also derive other standard HRV parameters, including rMSSD. As explained earlier, rMSSD is a measure of the root mean square of successive differences between normal heartbeats, which is a robust indicator of parasympathetic activity.

The outcome was assessed by measuring these rMSSD parameters and cardiac coherence **at the end of each of the nine appointments**. This repeated measurement approach allowed the researchers to track changes over time and observe the immediate effects of each biofeedback session, as well as cumulative effects across the three-week intervention period. Measuring at the end of each session helps to capture the acute impact of the biofeedback practice.

The use of a standardized, commercially available device like the EmWave Pro Plus® ensures a degree of consistency in measurement. However, it's worth noting that while PPG is a valid method for detecting heartbeats, it is an indirect measure of heart rate variability compared to electrocardiography (ECG), which is considered the gold standard. Nevertheless, for practical biofeedback applications, PPG-based devices are widely used and generally considered reliable for tracking changes in HRV and coherence.

This study employed a **Randomized Clinical Trial (RCT)** design, which is considered the gold standard for evaluating the effectiveness of interventions. In an RCT, participants are randomly assigned to either an intervention group or a control group. This random assignment is crucial because it helps to ensure that, on average, the two groups are similar in all characteristics (known and unknown) at the start of the study, except for the intervention they receive. This minimizes the risk of confounding variables influencing the results and strengthens the ability to attribute any observed differences to the intervention itself.

The study involved **two groups**:

1. **Biofeedback group:** Received the active cardiovascular biofeedback intervention using the EmWave Pro Plus® device and guided deep breathing techniques.

2. **Placebo group:** Received a placebo intervention. While the abstract doesn't specify the exact nature of the placebo, in biofeedback studies, it often involves a sham device or a procedure that mimics the intervention without providing active physiological feedback. The purpose of the placebo is to control for non-specific effects such as expectation, attention, and the Hawthorne effect (where participants modify their behavior in response to being observed).

**Randomization:** The abstract explicitly states that it was a "randomized clinical trial," indicating that participants were assigned to either the biofeedback or placebo group using a random process. This is a critical strength of the study design, as it helps to ensure that any differences observed between the groups are more likely due to the intervention rather than pre-existing differences between the participants.

**Blinding:** The abstract mentions a "placebo group," which strongly implies that participants were **blinded** to whether they were receiving the active biofeedback or the placebo. This means participants did not know which group they were in. Blinding participants is essential to prevent their expectations or beliefs about the intervention from influencing their physiological responses or self-reported outcomes. The abstract does not explicitly state whether the researchers or outcome assessors were also blinded (double-blinding), which would further reduce bias. In biofeedback studies, blinding the researchers providing the intervention can be challenging if they are directly operating the biofeedback device. However, blinding the outcome assessors (those analyzing the data) is usually feasible and important.

**Duration:** The intervention period spanned **three weeks**, during which participants in both groups attended **nine appointments**. This means approximately three sessions per week. The outcome measures (rMSSD and cardiac coherence) were assessed **at the end of each appointment**. This frequent measurement allows for tracking changes over the course of the intervention and understanding the immediate effects of each session. However, it does not provide information on the long-term sustainability of the effects after the intervention concludes.

**Statistical Approach:** The analysis was performed using **generalized estimation equations (GEE)**, with a significance level (alpha, α) set at **5% (0.05)**.

**Generalized Estimation Equations (GEE):** GEE is a statistical method particularly well-suited for analyzing longitudinal data, where measurements are taken repeatedly on the same individuals over time. It accounts for the correlation between repeated measurements within the same participant, which is common in studies like this where outcomes are assessed at the end of each of nine appointments. GEE allows researchers to model how an outcome changes over time and how this change differs between groups, even if the data doesn't perfectly fit assumptions of normality or equal variance.

**Alpha (α) = 5%:** This is the conventional threshold for statistical significance. A p-value less than 0.05 indicates that the observed result is unlikely to have occurred by chance alone, assuming the null hypothesis (no effect) is true.

**What this design can and cannot prove:**

**What it CAN prove:** As an RCT with a placebo control, this study design is strong in its ability to establish a **causal relationship** between cardiovascular biofeedback and changes in cardiac coherence. If significant differences are found between the biofeedback and placebo groups, it is highly probable that these differences are directly caused by the biofeedback intervention, rather than by other factors or mere expectation. The repeated measures design (9 appointments over 3 weeks) allows for tracking the trajectory of change and understanding if the effects accumulate over time.

**What it CANNOT prove:**

* **Long-term effects:** The three-week duration is relatively short. The study cannot determine if the improvements in cardiac coherence are sustained over longer periods (e.g., months or years) after the intervention ends, or if booster sessions are required.

* **General